Relapsed/refractory MM phase 3 trial comparing carfilzomib with dex vs carfilzomib with mezigdomide (Cel Mod) with dex. Please let me know if you have any patients who are refractory to Imid and anti CD38 therapy.
A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Placebo Plus Nivolumab as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma
